Kerr pharmacy care innovator tapped to lead N.C. board of pharmacy
RALEIGH, N.C. Rebecca Chater — who, as Kerr Health EVP, is one of the architects of many groundbreaking patient-care initiatives at the North Carolina retail drug innovator — has been elected president of the state’s board of pharmacy for 2010-2011.
Chater is in her second five-year term on the board, and will assume the role of president for the second time.
“It is an honor to serve in this capacity,” she said. “With some measure of national healthcare-reform legislation imminent, it is imperative we, as pharmacists, continue to assume an ever-increasing role in upholding and protecting public safety.”
Over the past decade at Kerr Drug, Chater has established herself as one of chain pharmacy’s most determined advocates for patient-care services by pharmacists that go beyond traditional counseling and basic medication therapy management. At Kerr, she directs the Care Management service line previously known as KDI Health Solutions, a healthcare provider organization specializing in preventive and chronic care services.
“In leading the development of clinical pharmacy services within Kerr Drug, Chater earned recognition for Kerr as 2006 Pinnacle Award recipient by the American Pharmacists Association Foundation; 2007, 2008 and 2009 National Medication Therapy Management Provider of the Year by Outcomes Pharmaceutical Health Care; 2008 North Carolina Provider of the Year by the American Diabetes Association,” noted Kerr in a statement.
Most recently, Chater was tapped for the 2008 Eagle Award by the North Carolina Alliance of Healthy Communities.
Intellipharmaceutics files new drug application for generic Protonix
TORONTO Intellipharmaceutics has filed an abbreviated new drug application for a generic drug designed to treat gastrointestinal issues, the drug maker said.
Intellipharmaceutics said its pantoprazole sodium delayed-release tablets — a generic version of Protonix — inhibits gastric acid secretion and is prescribed for the short-term treatment of such conditions as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
Sales of pantoprazole sodium delayed-release tablets in the United States were approximately $1.8 billion in 2009.
“I am extremely pleased with the progress we continue to make with the advancement of our product pipeline,” said Isa Odidi, Intellipharmaceutics CEO. “Protonix is the second ANDA we have filed with the FDA this year and, together with Focalin XR and Effexor XR, it represents another potential source of future revenue from our company’s ANDA pipeline.”
Injunction blocks Dr. Reddy’s generic Allegra D24
NEW YORK A U.S. District Court has granted French drug maker Sanofi-Aventis and Albany Molecular Research an injunction halting the launch of a generic version of one of its drugs made by Dr. Reddy’s Labs, Dr. Reddy’s said.
The U.S. District Court for the District of New Jersey blocked the release of Dr. Reddy’s fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets in the 180 mg and 240-mg strength, a generic version of Allegra D24, marketed by Sanofi-Aventis and discovered by Albany Molecular Research.
Dr. Reddy’s said it strongly disagreed with the lawsuit and intended to appeal. According to published reports, the Food and Drug Administration had approved Dr. Reddy’s version of the drug following a 30-month stay of approval resulting from a patent infringement lawsuit filed against the company when it tried to seek approval for the generic. The last patents covering Allegra D24 expire in December 2020.